Lexaria Bioscience (LEXX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience’s second human pilot study shows its DehydraTECH-processed Rybelsus capsules are well-tolerated with zero adverse events, outperforming the commercially available Rybelsus tablets, which showed higher instances of mild and moderate adverse effects. The study suggests that DehydraTECH technology may improve the delivery of semaglutide, potentially reducing side effects for users.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.